Provided by Tiger Trade Technology Pte. Ltd.

Kodiak Sciences Inc.

94.80
+3.684.04%
Post-market: 95.450.6500+0.69%19:59 EDT
Volume:4.92M
Turnover:460.07M
Market Cap:5.93B
PE:-22.80
High:98.80
Open:93.83
Low:88.48
Close:91.12
52wk High:98.80
52wk Low:10.94
Shares:62.58M
Float Shares:40.29M
Volume Ratio:0.50
T/O Rate:12.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1571
EPS(LYR):-4.3220
ROE:-368.37%
ROA:-60.45%
PB:97.10
PE(LYR):-21.93

Loading ...

Kodiak Sciences Shares up 123% After Co's Eye-Disease Drugs Meet Trial Goals

THOMSON REUTERS
·
Sep 28

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Oil Prices Rise

MT Newswires Live
·
Sep 28

Sector Update: Healthcare

MT Newswires Live
·
Sep 28

Nvidia, Meta, SpaceX, Kodiak Sciences, MongoDB, Boeing, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 28

The Stock Market Faces a Triple Threat but it Can Emerge Victorious

Dow Jones
·
Sep 28

Top Premarket Gainers

MT Newswires Live
·
Sep 28

Kodiak Sciences Rises After Eye-Disease Drugs Meet Trial Goals

Reuters
·
Sep 28

Kodiak Sciences Shares up 32% Premarket After Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Daybreak Trial in Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
Sep 28

Kodiak Sciences Says Zenkuda Meets Primary Endpoint in Phase 3 Daybreak Wet AMD Trial

Reuters
·
Sep 28

Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Pivotal Daybreak Trial in Wamd, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-Week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.

THOMSON REUTERS
·
Sep 28

Kodiak Sciences - Zenkuda Bla Planned for Q4 2026 to Include Five Positive Phase 3 Studies

THOMSON REUTERS
·
Sep 28

Kodiak Sciences Inc. - Zenkuda and Tabirafusp-Ted Demonstrated Safety Consistent with Established Safety Profile of Aflibercept

THOMSON REUTERS
·
Sep 28

Stocks to Watch: Kodiak Sciences, Circle Internet Group

Dow Jones
·
Sep 26

Kodiak Sciences Shares Surge Ahead of Phase 3 Readout

Dow Jones
·
Sep 26

Kodiak Sciences Upcoming Data Could Support Upside, UBS Says

MT Newswires Live
·
Sep 25

Kodiak Sciences (KOD) Initiated with a Hold at Goldman Sachs

TIPRANKS
·
Sep 24

Kodiak Sciences Price Target Maintained with a $58.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 17

KPK Seizes Rp6 Billion in Silmy Karim Foreign Residence Permit Extortion Case

Tempo
·
Aug 30

Kodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye Disease

TIPRANKS
·
Aug 22

Kodiak Sciences Price Target Maintained with a $58.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 17